These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18159322)

  • 1. Initial drug regimen for active tuberculosis cases in Montreal, 1995 to 1998.
    Rivest P; Tannenbaum TN
    Can J Infect Dis; 2001 Mar; 12(2):89-92. PubMed ID: 18159322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing drug resistance of Mycobacterium tuberculosis isolates in a medical center in northern Taiwan.
    Su WJ; Feng JY; Huang CC; Perng RP
    J Formos Med Assoc; 2008 Mar; 107(3):259-64. PubMed ID: 18400612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Isoniazid-Resistant Pulmonary Tuberculosis.
    Jhun BW; Koh WJ
    Tuberc Respir Dis (Seoul); 2020 Jan; 83(1):20-30. PubMed ID: 31905429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
    Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
    Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
    Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
    Chen C; Ortega F; Alameda L; Ferrer S; Simonsson US
    Eur J Pharm Sci; 2016 Oct; 93():319-33. PubMed ID: 27473307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-resistant tuberculosis in Budapest.
    Fodor T; Vadász I; Lõrinczi I
    Int J Tuberc Lung Dis; 1998 Sep; 2(9):732-5. PubMed ID: 9755927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance among Mycobacterium tuberculosis isolates in Lebanon.
    Hamze MM; Araj GF
    Int J Tuberc Lung Dis; 1997 Aug; 1(4):314-8. PubMed ID: 9432386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2008 and 2009. A report of the Australian Mycobacterium Reference Laboratory Network.
    Lumb R; Bastion I; Carter R; Jelfs P; Keehner T; Sievers A
    Commun Dis Intell Q Rep; 2011 Jun; 35(2):154-61. PubMed ID: 22010508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium tuberculosis resistance pattern against first-line drugs in patients from urban area.
    Cucunawangsih ; Wiwing V; Widysanto A; Lugito NP
    Int J Mycobacteriol; 2015 Dec; 4(4):302-5. PubMed ID: 26964812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.
    Liu X; Ren S; Zhang J; Xu D; Jiang F; Jiang P; Feng J; Deng F
    Ann Palliat Med; 2021 Jun; 10(6):6518-6534. PubMed ID: 34154362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW; Snider DE; Farer LS
    Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of extrapulmonary tuberculosis.
    Dutt AK; Stead WW
    Semin Respir Infect; 1989 Sep; 4(3):225-31. PubMed ID: 2688005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in demographic picture and increase of drug resistance in pulmonarytuberculosis in a 10-year interval in Taiwan.
    Tsao TC; Chiou W; Lin H; Wu T; Lin M; Yang P; Tsai Y
    Infection; 2002 Apr; 30(2):75-80. PubMed ID: 12018473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of Isoniazid, Rifampin and Ethambutol resistance to M. tuberculosis and M. bovis in multidrug resistant tuberculosis (MDR-TB) patients in Pakistan.
    Munir S; Mahmood N; Shahid S; Khan MI
    Microb Pathog; 2017 Sep; 110():262-274. PubMed ID: 28688981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
    Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
    PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.